New Data Showing that Transgene and NEC’s TG4050 induces strong and specific immune responses against tumors presented at AACR 15
Category: Myvac
Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC)
JP Delord, et al. ASCO 2022 Abstract available on the ASCO website – Download the poster here Poster Presentation
Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022
Transgene presented additional Phase I Data with TG4050 at ASCO 2022
Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022
Transgene to present updated positive preliminary data at ASCO 2022
Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients
MS Block et al. AACR 2022 Download the publication here
Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050
Transgene to present new positive preliminary Phase I Clinical data
Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients
MS Block et al.AACR 2022Read the abstract here – Download the poster herePoster Presentation
Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022
Transgene to present new positive preliminary Phase I data on TG4050
First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
Transgene to Present its Immuno-Oncology Expertise at Upcoming Scientific Conferences
20210302 – Transgene Scientific Conferences